Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3207 | Standard of care treatment Wiki | 0.71 |
drug1292 | Favipiravir Wiki | 0.21 |
drug2490 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the safety and immunogenicity of 2 doses of TAK-919 by intramuscular (IM) injection in healthy Japanese male and female adults.
Description: An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation subject administered an investigational medicinal product (IMP); it does not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs are defined as injection site pain, erythema/redness, swelling, induration, and axillary (underarm) swelling or tenderness ipsilateral to the side of injection.
Measure: Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination Time: Up to Day 7 after each vaccinationDescription: Solicited systemic AEs are defined as headache, fatigue, myalgia, arthralgia, nausea/vomiting, chills, and fever.
Measure: Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination Time: Up to Day 7 after each vaccinationDescription: Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.
Measure: Percentage of Participants with Unsolicited AEs for 28 Days After Each Vaccination Time: Up to Day 28 after each vaccinationDescription: An SAE is defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event.
Measure: Percentage of Participants with Serious AE (SAE) until Day 57 Time: Up to Day 57Description: GMT of serum bAb against SARS-CoV-2 will be measured by ligand-binding assay specific to the SARS-CoV-2 S protein.
Measure: Geometric Mean Titers (GMT) of Serum binding antibody (bAb) Against SARS-CoV-2 on Day 57 Time: Day 57Description: GMFR of serum bAb against SARS-CoV-2 will be measured by ligand-binding assay specific to the SARS-CoV-2 S protein.
Measure: Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57 Time: Day 57Description: SCR of serum bAb against SARS-CoV-2 will be measured by ligand-binding assay specific to the SARS-CoV-2 S protein. SCR is defined at percentage of participants with a change from below the limit of detection (LOD) to equal to or above LOD, OR, >= 4-fold rises from baseline.
Measure: Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57 Time: Day 57Description: GMT of serum bAb against SARS-CoV-2 will be measured by ligand-binding assay specific to the SARS-CoV-2 S protein.
Measure: GMT of Serum bAb Against SARS-CoV-2 on Day 29, Day 43, Day 209 and Day 394 Time: Day 29, Day 43, Day 209 and Day 394Description: GMFR of serum bAb against SARS-CoV-2 will be measured by ligand-binding assay specific to the SARS-CoV-2 S protein.
Measure: GMFR of Serum bAb Against SARS-CoV-2 on Day 29, Day 43, Day 209 and Day 394 Time: Day 29, Day 43, Day 209 and Day 394Description: SCR of serum bAb against SARS-CoV-2 will be measured by ligand-binding assay specific to the SARS-CoV-2 S protein. SCR is defined at percentage of participants with a change from below the LOD to equal to or above LOD, OR, >= 4-fold rises from baseline.
Measure: SCR of Serum bAb Against SARS-CoV-2 on Day 29, Day 43, Day 209 and Day 394 Time: Day 29, Day 43, Day 209 and Day 394Description: GMT of serum nAb against SARS-CoV-2 will be measured by assay specific to wild-type virus.
Measure: GMT of serum neutralizing antibody (nAb) against SARS-CoV-2 on Day 29, Day 43, Day 57, Day 209, and Day 394 Time: Day 29, Day 43, Day 57, Day 209, and Day 394Description: GMFR of serum nAb against SARS-CoV-2 will be measured by assay specific to wild-type virus.
Measure: GMFR of serum nAb against SARS-CoV-2 on Day 29, Day 43, Day 57, Day 209, and Day 394 Time: Day 29, Day 43, Day 57, Day 209, and Day 394Description: SCR of serum nAb against SARS-CoV-2 will be measured by assay specific to wild-type virus. SCR is defined at percentage of subjects with a change from below the lower limit of quantification (LLOQ) to equal to or above LLOQ, OR, >= 4-fold rises from baseline.
Measure: SCR of serum nAb against SARS-CoV-2 on Day 29, Day 43, Day 57, Day 209, and Day 394 Time: Day 29, Day 43, Day 57, Day 209, and Day 394Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports